Back to top
more

Novo Nordisk (NVO)

(Real Time Quote from BATS)

$116.01 USD

116.01
312,096

-2.00 (-1.70%)

Updated Oct 2, 2024 09:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline

Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.

Gilead Collaborates With Insitro to Develop NASH Therapies

Gilead (GILD) collaborates with data-driven company, Insitro, to harness the power of computers to discover and develop therapies for treating NASH (fatty liver).

Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal

Key highlights of the past week are collaborations and pipeline updates.

Gilead to Collaborate with Novo Nordisk for NASH Treatment

Gilead Sciences (GILD) will collaborate with Novo Nordisk to develop treatments for liver disease, NASH.

Sangamo Rises on Positive Phase I/II Hemophilia Study Data

Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.

Kevin Cook headshot

Bull of the Day: DexCom (DXCM)

Diabetes care goes beyond the finger prick to streaming digital data with this rapidly growing innovator

Lilly to Bring Half-Priced Version of Popular Humalog Insulin

Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.

What's in the Cards for Aeterna (AEZS) This Earnings Season?

Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.

Ophthotech's (OPHT) Q4 Loss Wider, Gene Therapy in Focus

Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.

Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates

Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).

Sweta Killa headshot

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct

Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.

Seattle Genetics' Adcetris Gets EC Nod for Label Expansion

Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.

Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth

Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.

Sanofi's Myeloma Candidate Meets Goal in Phase III Study

Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.

Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer

Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.

Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat

Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.

Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.

Sweta Killa headshot

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Merck (MRK) Q4 Earnings Coming Up: What's in the Cards?

Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive fourth-quarter sales. However, genericization of key drugs and increasing competition are concerns.

Lilly Stops Lartruvo Promotion as Confirmatory Study Fails

Eli Lilly's (LLY) Lartruvo combo is unable to demonstrate the clinical benefit for the primary endpoint of OS rate in a phase III study related to treating patients with metastatic soft tissue sarcoma.

5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019

Novo Nordisk (NVO) has a strong presence in the Diabetes care market and its top line is driven by strong performance of products like Victoza.

Novo Nordisk Boasts Strong Diabetes Presence and Pipeline

Novo Nordisk (NVO) has a strong presence in the Diabetes Care market and boasts a strong pipeline, with focus on therapeutic proteins within insulin.

Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial

Zafgen's (ZFGN) stock plunges significantly as the FDA placed a clinical hold on the company's first trial on experimental diabetes drug, ZGN-1061.

The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources

The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources